1. Introduction {#sec1-marinedrugs-16-00278}
===============

Soft corals have been known to be the organisms possessing secondary metabolites with high diversity in chemical structures \[[@B1-marinedrugs-16-00278]\]. Since 1975, many cembranoid-type natural products with diverse and important biological activities have been isolated from *Sinularia flexibilis* \[[@B2-marinedrugs-16-00278],[@B3-marinedrugs-16-00278],[@B4-marinedrugs-16-00278],[@B5-marinedrugs-16-00278],[@B6-marinedrugs-16-00278],[@B7-marinedrugs-16-00278],[@B8-marinedrugs-16-00278],[@B9-marinedrugs-16-00278],[@B10-marinedrugs-16-00278],[@B11-marinedrugs-16-00278],[@B12-marinedrugs-16-00278],[@B13-marinedrugs-16-00278]\]. In previous studies of the chemical constituents of Taiwanese soft corals, numerous marine metabolites with cytotoxic \[[@B14-marinedrugs-16-00278],[@B15-marinedrugs-16-00278]\], neuroprotective \[[@B16-marinedrugs-16-00278]\], and anti-inflammatory activities \[[@B17-marinedrugs-16-00278],[@B18-marinedrugs-16-00278],[@B19-marinedrugs-16-00278]\] were also found from *Sinularia flexibilis*. Some cembranolides, possessing an α-methylene lactone ring, have been discovered as potent cytotoxic agents to a limited panel of cancer cell lines, for example, 14-deoxycrassin \[[@B20-marinedrugs-16-00278]\], and as significant anti-inflammatory agents, for example, sinulariolone acetate \[[@B21-marinedrugs-16-00278]\]. Additionally, cembranoids and related compounds from other coral species were also found to have notable antiviral \[[@B22-marinedrugs-16-00278]\], anti-inflammatory \[[@B23-marinedrugs-16-00278],[@B24-marinedrugs-16-00278]\], and antiproliferative \[[@B25-marinedrugs-16-00278],[@B26-marinedrugs-16-00278],[@B27-marinedrugs-16-00278],[@B28-marinedrugs-16-00278]\] activities. A wide variety of chemical diversity and biological activity of cembranoids encouraged us to search for more natural products from soft coral *S*. *flexibilis*, collected off the waters of Taiwan. Herein, we report the isolation of five new cembrane-related metabolites, namely, flexbilisins D and E (**1** and **2**), secoflexibilisolides A and B (**3** and **4**), and a cembranolide flexibilisolide H (**5**) ([Figure 1](#marinedrugs-16-00278-f001){ref-type="fig"}), and nine known compounds, including 6*R*-hydroxysinulariolide (**6**) \[[@B3-marinedrugs-16-00278]\], 11-dehydrosinulariolide (**7**) \[[@B18-marinedrugs-16-00278]\], 11-*epi*-sinulariolide acetate (**8**) \[[@B13-marinedrugs-16-00278]\], 14-deoxycrassin (**9**) \[[@B20-marinedrugs-16-00278]\], 3,4:8,11-bisepoxy-7-acetoxycembra-15(17)-en-1,12-olide (**10**) \[[@B6-marinedrugs-16-00278]\], sinulariolide (**11**) \[[@B2-marinedrugs-16-00278]\], sinulaflexiolide E (**12**) \[[@B10-marinedrugs-16-00278]\], querciformolide A (**13**) \[[@B21-marinedrugs-16-00278]\], and flexibilisquinone (**14**) \[[@B19-marinedrugs-16-00278]\] ([Figure 2](#marinedrugs-16-00278-f002){ref-type="fig"}). Their structures were established by spectroscopic analysis including infrared (IR), mass spectrometry (MS), and nuclear magnetic resonance (NMR) data ([Figures S1--S14](#app1-marinedrugs-16-00278){ref-type="app"}), as well as chemical transformation. The biogenetic origins of **3** and **4** were postulated to demonstrate the relationship between stereochemistry and biogenetic implications. The cytotoxicity of the isolates toward a limited panel of cancer cell lines and their inhibition of superoxide anion generation and elastase release in *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLF/CB)-induced human neutrophils were also investigated.

2. Results and Discussion {#sec2-marinedrugs-16-00278}
=========================

Flexbilisin D (**1**) was obtained as a colorless oil and its high-resolution electrospray ionization mass spectrometry (HRESIMS) (*m/z* 371.2196 \[M + Na\]^+^) data established the molecular formula of C~21~H~32~O~4~, indicating six degrees of unsaturation. The IR spectrum showed the absorption bands of carbonyl group (1716 cm^−1^) and double bond (1647 cm^−1^). The NMR data ([Table 1](#marinedrugs-16-00278-t001){ref-type="table"}), including ^13^C NMR and distortion less enhancement by polarization transfer (DEPT) spectra, displayed 21 carbin signals which can be classified as three methyls (*δ*c 15.3, 17.0, 17.8), one methoxy (*δ*c 52.0), seven *sp*^3^ methylene (*δ*c 22.2, 24.6, 27.4, 31.5, 33.0, 36.0, 36.9), one *sp*^2^ methylene (*δ*c 124.4), three *sp*^3^ methine (*δ*c 35.2, 60.1, 61.9), one *sp*^2^ methine (*δ*c 126.5), two *sp*^3^ quaternary (*δ*c 60.2, 60.8), and three *sp*^2^ quaternary (134.2, 142.7, 167.3) carbons. The ^13^C NMR signals at *δ*c 142.7 (C), *δ*c 124.4 (CH~2~) and the ^1^H NMR signals at *δ*~H~ 6.26 (1H, s) and *δ*~H~ 5.48 (1H, s) revealed the presence of a 1,1-disubstituted double bond, while those at *δ*c 134.2 (CH), *δ*c 126.5 (C), and *δ*~H~ 5.18 (1H, t, *J* = 5.6 Hz) are indicative of a trisubstituted double bond. Two trisubstituted epoxides were identified from the NMR signals at *δ*c 61.9 CH, 60.8 C and 60.2 C, 60.1 CH; *δ*~H~ 2.65 dd, *J* = 10.0 and 3.2 Hz; 2.81 dd, *J* = 10.0 and 4.0 Hz. The molecular skeleton of **1** was established by the above results, as well as the correlations spectroscopy (COSY) and heteronuclear multiple bond correlation (HMBC) correlations as shown in [Figure 3](#marinedrugs-16-00278-f003){ref-type="fig"}. By analysis of the COSY correlations, it was possible to identify three partial structures (a--c). The fact that the methyl ester group \[CO (*δ*c 167.3)/OMe (*δ*c 52.0; *δ*~H~ 3.76)\] was on C-15 (*δ*c 142.7) was confirmed by the HMBC correlation from H~2~-17 (*δ*~H~ 6.26, 5.48) to C-16 (*δ*c 167.3). The two epoxides were assigned at 3,4- and 11,12-positions with methyl substituents at C-4 (*δ*c 60.2) and C-12 (*δ*c 60.8) according to HMBC correlations from H~3~-18 (*δ*~H~ 1.29) to C-3 (*δ*c 60.1), C-4, and C-5 (*δ*c 36.9), as well as H~3~-20 (*δ*~H~ 1.23) to C-11(*δ*c 61.9), C-12, and C-13 (*δ*c 33.0), respectively. Together with other key HMBC correlations from H~3~-19 (*δ*~H~ 1.65) to C-7 (*δ*c 126.5), C-8 (*δ*c 134.2), and C-9 (*δ*c 36.0), as well as H~2~-17 to C-1 (*δ*c 35.2), C-15, and C-16 permitted the establishment of the carbon skeleton.

The relative configuration of **1** was determined by the nuclear Overhauser effect spectroscopy (NOESY) experiment as shown in [Figure 4](#marinedrugs-16-00278-f004){ref-type="fig"}. Assuming that H-1 is α-oriented, which showed NOESY correlations to one of H~2~-2 (*δ*~H~ 1.36) and one of H~2~-13 (*δ*~H~ 1.70); thus, another of H~2~-2 (*δ*~H~ 2.05) and H~2~-13 (*δ*~H~ 1.20) were β-oriented. Two *trans* epoxides were then assigned according to the NOESY correlations from H-11 to H-13*β* and from H-13α to H~3~-20, as well as those from H~3~-18 to H-2α. The proposed structure of **1** is in agreement with the most stable conformation ([Figure 4](#marinedrugs-16-00278-f004){ref-type="fig"}) generated by an energy-minimized (MM2) force field calculation \[[@B29-marinedrugs-16-00278]\]. Consequently, the relative configurations of C-1, C-3, C-11, and C-12 were determined as 1*R*\*, 3*S*\*, 4*S*\*, 11*R*\*, 12*R*\* ([Figure 4](#marinedrugs-16-00278-f004){ref-type="fig"}).

Flexibilisin E (**2**) had a molecular formula C~21~H~32~O~5~ as deduced from HRESIMS data. The ^1^H and ^13^C NMR spectra showed that the structure of **2** closely resembled that of **1**. By comparing their NMR data ([Table 1](#marinedrugs-16-00278-t001){ref-type="table"}), significant differences in chemical shifts were observed at C-11 (*δ*c 61.9 for **1**; 213.6 for **2**), C-12 (*δ*c 60.8 for **1**; 78.8 for **2**), and C-20 (*δ*c 17.0 for **1**; 25.7 for **2**), suggesting that **2** is a 12-hydroxy-11-oxo derivative of **1**. This was supported by the COSY and HMBC correlations ([Figure 3](#marinedrugs-16-00278-f003){ref-type="fig"}). The structure and absolute configurations of the stereogenic centers of **2** were confirmed by an alkaline hydrolysis of 11-dehydrosinulariolide (**7**), whose absolute configurations at C-1, C-3, C-4, and C-12 were determined as 1*R*, 3*S*, 4*S*, and 12*R*, respectively, based on a single-crystal X-ray diffraction analysis \[[@B18-marinedrugs-16-00278]\]. Accordingly, the structure of **2** was determined as shown in [Figure 1](#marinedrugs-16-00278-f001){ref-type="fig"}.

Secoflexibilisolide A (**3**) was isolated as a colorless oil and its molecular formula was established as C~20~H~28~O~5~ by the observation of a sodiated molecular ion peak at *m/z* 371.1831 (calcd. for 371.1829 \[M + Na\]^+^) in the HRESIMS, indicating seven degrees of unsaturation. Its IR absorption bands suggested the presence of hydroxy (3450 cm^−1^) and carbonyl (1765 and 1671 cm^−1^) groups. Three spin systems (a--c), inferred by analysis of the COSY correlations, were constructed as shown in [Figure 5](#marinedrugs-16-00278-f005){ref-type="fig"}. A bicyclo\[4.3.0\]nonane ring system was established by the HMBC correlations from H~3~-20 (*δ*~H~ 1.39) to C-11 (*δ*c 85.3), C-12 (*δ*c 84.7), and C-13 (*δ*c 30.4); from H~2~-10 (*δ*~H~ 2.05, 1.68) to C-11 and C-12; and from H~2~-17 (*δ*~H~ 2.26, 1.66) to C-1 (*δ*c 34.5), C-15 (*δ*c 60.9), and C-16 (*δ*c 177.6). In addition, a γ--lactone ring between C-16 and C-11 was evidenced by the IR absorption band at 1765 cm^−1^, which is consistent with perhydroindan analogues \[[@B30-marinedrugs-16-00278]\]. A methyl-substituted epoxy group was evidenced by the HMBC correlations from H~3~-18 (*δ*~H~ 1.28) to C-3 (*δ*c 61.9), C-4 (*δ*c 58.8), and C-5 (*δ*c 41.2), while an acetyl group was found to be located at C-7 by the HMBC correlations from H~3~-19 (*δ*~H~ 2.26) to C-7 (*δ*c 134.0) and C-8 (*δ*c 198.3). Accordingly, the planar structure of **3** was deduced as shown in [Figure 5](#marinedrugs-16-00278-f005){ref-type="fig"}.

Compound **3** can be hypothesized to derive from a precursor with the cembranoid-type skeleton. As shown in [Scheme 1](#marinedrugs-16-00278-sch001){ref-type="scheme"}, flexibilisolide D, which was also isolated from this coral \[[@B17-marinedrugs-16-00278]\], was suggested as a precursor. Flexibilisolide D was converted to intermediate I by oxidative cleavage and Michael addition. Reduction of the carboxylic acid of the cyclobutane intermediate (II), derived from I by the aldol condensation, would produce an alcohol functionality in III. Rearrangement of the hydroxymethyl cyclobutane through a reductive ring opening in III resulted in a formation of the cyclopentane ring in **3**. This suggested that the configurations of C-1, C-3, C-4, and C-12 should be the same as those of flexibilisolide D and related analogues possessing a 3,4-epoxide group, isolated previously from this soft coral \[[@B17-marinedrugs-16-00278]\]. The relative configurations of C-11 and C-15 were determined by a combination of NOESY correlations ([Figure 5](#marinedrugs-16-00278-f005){ref-type="fig"}) and pyridine-induced solvent shift experiment \[[@B31-marinedrugs-16-00278]\]. The NOESY correlations from H~3~-20 to H~2~-10 allowed the assignment of the lactone ring as α-oriented. However, the present NOESY data were unable to fully confirm the orientation of OH-11. As a result, the pyridine-induced solvent shift experiment was applied on **3**. H-2β (*δ*~H~ 1.66 in pyridine), which is 1,3-diaxial to OH-11, was found to be downfield shifted by 0.28 ppm with respect to H-2β, measured in CDCl~3~ ([Table 2](#marinedrugs-16-00278-t002){ref-type="table"}), suggesting the β-orientation of OH-11. Consequently, the relative configurations 1*R*\*, 3*S*\*, 4*S*\*, 11*S*\*, 12*S*\*, 15*R*\* were suggested for **3**.

The molecular formula of **4** was found to be C~20~H~28~O~6~ as deduced from the HRESIMS and ^13^C NMR data, suggesting seven degrees of unsaturation. The ^13^C NMR data of **4** ([Table 3](#marinedrugs-16-00278-t003){ref-type="table"}) showed signals attributable to two double bonds (*δ*c 139.5, 126.0, 136.9, 124.1), one ketone carbonyl (*δ*c 205.6), and two ester carbonyls (*δ*c 175.4, 165.3), which accounted for five degrees of unsaturation. Accordingly, the structure of **4** may contain two rings. From the COSY spectrum of **4**, it was possible to suggest the presence of three proton sequences for H~2~-13/H~2~-14/H-1/H-2/H-3, H~2~-5/H-6/H-7, and H~2~-9/H~2~-10 (a--c, respectively; [Figure 6](#marinedrugs-16-00278-f006){ref-type="fig"}). Key HMBC correlations from H~3~-20 (*δ*~H~ 1.64) to C-12 (*δ*c 205.6) and C-13 (*δ*c 39.4); from H~2~-17 (*δ*~H~ 6.40, 5.12) to C-15 (*δ*c 139.5), C-16 (*δ*c 165.3), and C-1 (*δ*c 35.9); from H~3~-18 (*δ*~H~ 1.00) to C-3 (*δ*c 83.0), C-4 (*δ*c 72.5), and C-5 (*δ*c 41.3); and from H~3~-19 (*δ*~H~ 1.04) to C-7 (*δ*c 136.9), C-8 (*δ*c 83.9), and C-9 (*δ*c 33.9); as well as H~2~-10 (*δ*~H~ 2.05, 1.94) to C-11 (*δ*c 175.4) were observed, allowing to establish the planar structure of **4** as shown in [Figure 6](#marinedrugs-16-00278-f006){ref-type="fig"}.

In the NOESY spectrum of **4**, correlations from H-2α to both H-1 and H-3, and from H~3~-18 to H-3 revealed that H-1 and H-3 are on the same face of the lactone ring. Biogenetically, **4** could be derived from sinuflexolide, which has been reported from the same coral \[[@B12-marinedrugs-16-00278]\], via an oxidative cleavage of the diol groups, epimerization of the vinyl alcohol, and subsequent esterification ([Scheme 2](#marinedrugs-16-00278-sch002){ref-type="scheme"}). This suggested that the configuration of C-4 should be the same as that of sinuflexolide. Consequently, the relative configurations 1*S*\*, 3*S*\*, 4*R*\* were suggested for **4**. The configuration of C-8 remains undetermined.

The ^13^C NMR data ([Table 3](#marinedrugs-16-00278-t003){ref-type="table"}) and the HRESIMS of **5** showed that it has the same molecular formula as flexibilisolide G \[[@B17-marinedrugs-16-00278]\], that is, C~22~H~32~O~7~. They also have similar functional groups, including an α-exomethylene-ε-lactone ring, an acetoxyl group, and a methyl-substituted epoxy group. However, the obvious difference between the two compounds is that the 6,7-double bond in flexibilisolide G is isomerized to an exocyclic double bond at C-8 in **5**. In addition, the hydroperoxy group at C-7 in flexibilisolide G was found to migrate to C-8 in **5**. The above findings were further confirmed by COSY and HMBC correlations. The 1*R*\*, 12*R*\* configuration of the α-exomethylene-ε-lactone ring was deduced based on the NOESY correlations from H-1 to H-14α, from H~3~-20 to H-13β, and from H-14β to H-13β. In addition, NOESY correlations from H-11 to both H-7 and H-1 as well as H-1 to H-4 suggested the relative configurations of C-3, C-4, C-7, and C-11 as shown in [Figure 4](#marinedrugs-16-00278-f004){ref-type="fig"}.

The cytotoxicitiy of **1**, **2**, and **4**--**14** against P-388 (murine leukemia), K-562 (human erythromyeloblastoid leukemia), and HT-29 (human colon carcinoma cells) cell lines was investigated. The results showed that **7**--**9** and **11** exhibited cytotoxic activity toward P-388 and K-562 cancer cell lines with half maximal inhibitory concentration (IC~50~) values ranging from 6.9 μM to 26.7 μM ([Table 4](#marinedrugs-16-00278-t004){ref-type="table"}). Among them, **7** showed selective cytotoxicity toward P-388, while **8** was found to show potent activity and selectivity toward P-388 and HT-29 cancer cell lines. Compounds **1**, **2**, **4**--**6**, **10**, and **12**--**14** were nontoxic toward these cancer cell lines (IC~50~ values \> 40 μM). The anti-inflammatory effect of **1**, **2**, and **4**--**14** was also studied by measuring their ability to suppress *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLF-CB)-induced superoxide anion (O~2~^−•^) generation and elastase release in human neutrophils. The results revealed that, at a concentration of 10 μM, **9** exhibited significant inhibition toward superoxide anion generation and elastase release with IC~50~ values of 10.8 ± 0.38 and 11.0 ± 1.52 μM, respectively.

3. Experimental Section {#sec3-marinedrugs-16-00278}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00278}
------------------------------------

Optical rotations were measured on a JASCO P-1020 polarimeter (JASCO Corpotation, Tokyo, Japan). IR spectra were recorded on a JASCO FT/IR-4100 infrared spectrophotometer (JASCO Corporation) (Varian Inc., Palo Alto, CA, USA). NMR spectra were recorded on 400 MHz (or 500 MHz) for ^1^H and 100 MHz (or 125 MHz) for ^13^C in CDCl~3~ or C~6~D~6~. LRMS or HRMS were obtained by electrospray ionization (ESI) on a Bucker APEX II mass spectrometer (Bruker, Bremen, Germany). Silica gel (230--400 mesh, Merck, Darmstadt, Germany) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical thin-layer chromatography (TLC). High-performance liquid chromatography was performed on a Hitachi L-7100 (HPLC) (Hitachi Ltd., Tokyo, Japan) apparatus with a Merck Hibar Si-60 column (250 mm × 21.2 mm, 8 μm) and on a Hitachi L-2455 (HPLC) (Hitachi Ltd., Tokyo, Japan) apparatus with a Sciences Inc. (GL Science, Tokyo, Japan) ODS-3 C18 column (250 mm × 20 mm, 5 μm).

3.2. Animal Material {#sec3dot2-marinedrugs-16-00278}
--------------------

The soft coral *Sinularia flexibilis* was collected by scuba diving off the coast of Liuqiu, Taiwan, in October 2011, at a depth of 10--15 m, and stored in the freezer until extraction. A voucher specimen was deposited in the Department of Marine Biotechnology and Resource, National Sun Yet-sen University.

3.3. Extraction and Separation {#sec3dot3-marinedrugs-16-00278}
------------------------------

Sliced bodies of *S. flexibilis* were exhaustively extracted with EtOAc (2 L × 5). The EtOAc extract (40.0 g) was chromatographed over silica gel by column chromatography using hexane, EtOAc--hexane (1:100 and gradually increasing the proportion of EtOAc to 10:1), EtOAc, and then Me~2~CO--EtOAc (1:100 and gradually increasing the proportion of Me~2~CO to 10:1), and subsequently Me~2~CO as eluents to yield 26 fractions. Fraction 16, eluting with hexane--EtOAc (3:1), was further applied on a silica gel column (240 g) using hexane--EtOAc (8:1) to yield five subfractions (A--E). Subfraction 16-C was purified by normal-phase HPLC using hexane--Me~2~CO (8:1) to afford **1** (3.4 mg). Fraction 18, eluting with hexane-EtOAc (1:1), was further purified by RP-18 silica gel and using a mixture of MeOH-H~2~O (1.5:1) to yield seven subfractions (A--G). Subfraction 18-B was purified by reversed-phase HPLC using MeCN-H~2~O (1:2) to afford **3** (1.0 mg). Subfraction 18-D was purified over silica gel column (50 g) using hexane--EtOAc (2:1) to obtain **4** (3.2 mg). Fraction 19, eluting with hexane--EtOAc (1:2), was chromatographed on silica gel (240 g) using hexane--EtOAc (5:1) to yield six subfractions (A--F). Subfraction 19-B was purified on RP-18 silica gel using MeOH--H~2~O (1:1) and subsequently by RP-HPLC with MeOH--H~2~O (1.5:1) to afford **7** (280.4 mg) and **14** (2.9 mg). Subfraction 19-E was purified by RP-HPLC with MeCN--H~2~O (2:1) to yield **2** (94.6 mg), **8** (84.5 mg), and **9** (11.2 mg). Fraction 20, eluting with hexane--EtOAc (2:1), was further purified over silica gel column (200 g) and eluted with hexane--EtOAc (2:1) to yield five subfractions (A--E). Compounds **5** (2.1 mg) and **10** (123.7 mg) were obtained from subfraction 20-C using NP-HPLC (hexane--Me~2~CO, 4:1). Subfraction 20-E was isolated repeatedly over silica gel column (50 g) using hexane--Me~2~CO (3:1) as eluent, followed by RP-HPLC (MeCN--H~2~O, 1:1.5) to afford **6** (4.8 mg), **11** (9.5 mg), **12** (5.1 mg), and **13** (1.0 mg).

Flexibilisin D (**1**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{19}$ −245 (*c* 0.85, CHCl~3~); IR (KBr) v~max~ 2933, 1716, 1647, 1453, 1244, 1149, and 1074 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-16-00278-t001){ref-type="table"}; ESIMS *m/z* 371 \[M + Na\]^+^; HRESIMS *m/z* 371.2196 \[M + Na\]^+^ (calcd. for C~21~H~32~O~4~Na, 371.2198).

Flexibilisin E (**2**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +26 (*c* 0.57, CHCl~3~); IR (KBr) v~max~ 3481, 2927, 1713, 1627, 1460, 1438, 1387, 1252, 1159, 946, 816, and 755 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-16-00278-t001){ref-type="table"}; ESIMS *m/z* 387 \[M + Na\]^+^; HRESIMS *m/z* 387.2145 \[M + Na\]^+^ (calcd. for C~21~H~32~O~5~Na, 387.2147).

Secoflexibilisolide A (**3**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ −580 (*c* 0.28, CHCl~3~); IR (KBr) v~max~ 3450, 2924, 1766, 1672, 1627, 1380, 1232, 1175, 1101, 1078, 1030, and 1026 cm^−1^; ^1^H and ^13^C NMR data, see [Table 2](#marinedrugs-16-00278-t002){ref-type="table"}; ESIMS *m/z* 371 \[M + Na\]^+^; HRESIMS *m/z* 371.1831 \[M + Na\]^+^ (calcd. for C~20~H~28~O~5~Na, 371.1829).

Secoflexibilisolide B (**4**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{19}$ −56 (*c* 0.91, CHCl~3~); IR (KBr) v~max~ 3501, 2924, 1705, 1647, 1515, 1267, and 1153 cm^−1^; ^1^H and ^13^C NMR data, see [Table 3](#marinedrugs-16-00278-t003){ref-type="table"}; ESIMS *m/z* 387 \[M + Na\]^+^; HRESIMS *m/z* 387.1779 \[M + Na\]^+^ (calcd. for C~20~H~28~O~6~Na, 387.1778).

Flexibilisolide H (**5**): white powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{19}$ −12 (*c* 0.60, CHCl~3~); IR (KBr) v~max~ 3391, 2934, 1739, 1711, 1621, 1239, 1236, 1141, 1065, and 1048 cm^−1^; ^1^H and ^13^C NMR data, see [Table 3](#marinedrugs-16-00278-t003){ref-type="table"}; ESIMS *m/z* 431 \[M + Na\]^+^; HRESIMS *m/z* 431.2047 \[M + Na\]^+^ (calcd. for C~22~H~32~O~7~Na, 431.2046).

3.4. Alkaline Hydrolysis of **7** {#sec3dot4-marinedrugs-16-00278}
---------------------------------

Compound **7** (3.5 mg) was dissolved in 1 N methanolic NaOH solution (1 mL), and the mixture was stirred at 0 °C for 12 h. The reaction mixture was neutralized with 0.1 N HCl (*aq*). After evaporation of the solvent, the residue was extracted with CHCl~3~, and subsequently purified by HPLC using MeOH--H~2~O (3:1) as eluent to yield a methyl ester (1.1 mg, 31.4%; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +48 (*c* 0.28, CHCl~3~; ^1^H and ^13^C NMR spectra, [Supplementary materials, Figures S4 and S5](#app1-marinedrugs-16-00278){ref-type="app"}), which was identified as **2**.

3.5. Cytotoxicity Testing {#sec3dot5-marinedrugs-16-00278}
-------------------------

Cell lines were purchased from the American Type Cultural Collection (ATCC). Cytotoxicity assay of **1**, **2**, and **4**--**14** were performed using Alamar Blue Assay \[[@B32-marinedrugs-16-00278],[@B33-marinedrugs-16-00278]\].

3.6. In Vitro Anti-Inflammatory Assay {#sec3dot6-marinedrugs-16-00278}
-------------------------------------

Human neutrophils were obtained from whole blood using dextran sedimentation and Ficoll centrifugation. Measurements of superoxide anion generation and elastase release were performed according to previously described procedures \[[@B34-marinedrugs-16-00278],[@B35-marinedrugs-16-00278]\]. Idelalisib was used as a positive control, of which the IC~50~ values for inhibition of superoxide anion generation and elastase release were 0.07 ± 0.01 and 0.28 ± 0.09 μM, respectively.

4. Conclusions {#sec4-marinedrugs-16-00278}
==============

Five new diterpenoids and nine known compounds were isolated and characterized from the marine soft coral *Sinularia flexibilis*. The previously unreported **3**, containing a bicyclo\[4.3.0\]nonane ring system, was proposed be derived from flexibilisolide D. Compounds **7** and **8** showed selective cytotoxicity toward P388 cancer cell line, while **8** also exhibited significant cytotoxicity toward HT-29 cancer cells. Compound **9** displayed weaker cytotoxicity than **7** and **8**, but displayed potent inhibitory activities for superoxide anion generation and elastase release in (fMLF-CB)-induced human neutrophils.

^1^H and ^13^C spectra of compounds **1**--**14** and the hydrolyzed product of **7** are available online at <http://www.mdpi.com/1660-3397/16/8/278/s1>. Figure S1: ^1^H NMR spectrum of compound **1** in CDCl~3~, Figure S2: ^13^C NMR spectrum of compound **1** in CDCl~3~, Figure S3: ^1^H NMR spectrum of compound **2** in CDCl~3~, Figure S4: ^1^H NMR spectra of compound **2** and hydrolyzed product of **7** in CDCl~3~, Figure S5: ^13^C NMR spectra of compound **2** and hydrolyzed product of **7** in CDCl~3~, Figure S6: ^13^C NMR spectrum of compound **2** in CDCl~3~, Figure S7: ^1^H NMR spectrum of compound **3** in CDCl~3~, Figure S8: ^1^H NMR spectrum of compound **3** in pyridine-*d~5~*, Figure S9: ^13^C NMR spectrum of compound **3** in CDCl~3~, Figure S10: ^1^H--^1^H COSY spectrum of **3** in pyridine-*d~5~*, Figure S11: ^1^H NMR spectrum of compound **4** in C~6~D~6~, Figure S12: ^13^C NMR spectrum of compound **4** in C~6~D~6~, Figure S13: ^1^H NMR spectrum of compound **5** in CDCl~3~, Figure S14: ^13^C NMR spectrum of compound **5** in CDCl~3~, Figure S15: ^1^H NMR spectrum of compound **6** in CDCl~3~, Figure S16: ^13^C NMR spectrum of compound **6** in CDCl~3~, Figure S17: ^1^H NMR spectrum of compound **7** in CDCl~3~, Figure S18: ^13^C NMR spectrum of compound **7** in CDCl~3~, Figure S19: ^1^H NMR spectrum of compound **8** in CDCl~3~, Figure S20: ^13^C NMR spectrum of compound **8** in CDCl~3~, Figure S21: ^1^H NMR spectrum of compound **9** in CDCl~3~, Figure S22: ^13^C NMR spectrum of compound **9** in CDCl~3~, Figure S23: ^1^H NMR spectrum of compound **10** in CDCl~3~, Figure S24: ^13^C NMR spectrum of compound **10** in CDCl~3~, Figure S25: ^1^H NMR spectrum of compound **11** in CDCl~3~, Figure S26: ^13^C NMR spectrum of compound **11** in CDCl~3~, Figure S27: ^1^H NMR spectrum of compound **12** in CDCl~3~, Figure S28: ^13^C NMR spectrum of compound **12** in CDCl~3~, Figure S29: ^1^H NMR spectrum of compound **13** in CDCl~3~, Figure S30: ^13^C NMR spectrum of compound **13** in CDCl~3~, Figure S31: ^1^H NMR spectrum of compound **14** in CDCl~3~, Figure S32: ^13^C NMR spectrum of compound **14** in CDCl~3~.

###### 

Click here for additional data file.

J.-H.S. designed and guided the whole experiment and contributed to manuscript preparation. T.-Z.H. and C.-H.C. make the structure elucidation and manuscript preparation. C.-H.W. and C.-Y.H. perform the experiment. C.-Y.H. and T.-L.H. performed bioassays. C.-F.D. identified the soft coral.

This work was supported by grants from Ministry of Science and Technology of Taiwan (MOST104-2113-M-110-006 and 105-2113-M-110-002), and the National Sun Yat-sen University-Kaohsiung Medical University (NSYSU-KMU) Joint Research Projects (NSYSUKMU 105-I008 and 106-I007) awarded to J.-H.S.

The authors declare no conflicts of interest.

Figures, Schemes and Tables
===========================

![Structures of **1**--**5**.](marinedrugs-16-00278-g001){#marinedrugs-16-00278-f001}

![Structures of metabolites **6**−**14**.](marinedrugs-16-00278-g002){#marinedrugs-16-00278-f002}

![Key COSY and HMBC correlations for **1** and **2**.](marinedrugs-16-00278-g003){#marinedrugs-16-00278-f003}

![Selective NOESY correlations for **1** and **5**.](marinedrugs-16-00278-g004){#marinedrugs-16-00278-f004}

![Key COSY and HMBC correlations and selective NOESY correlations for **3**.](marinedrugs-16-00278-g005){#marinedrugs-16-00278-f005}

![Proposed biosynthetic pathway for **3**.](marinedrugs-16-00278-sch001){#marinedrugs-16-00278-sch001}

![Key COSY and HMBC correlations for **4**.](marinedrugs-16-00278-g006){#marinedrugs-16-00278-f006}

![Proposed biosynthetic pathway for **4**.](marinedrugs-16-00278-sch002){#marinedrugs-16-00278-sch002}

marinedrugs-16-00278-t001_Table 1

###### 

^1^H and ^13^C NMR spectroscopic data of **1** and **2**.

  -----------------------------------------------------------------------------------------------
  Position   1                      2                                             
  ---------- ---------------------- --------------- ----------------------------- ---------------
  1          2.85, m                35.2 (CH)       2.79, m                       36.5 (CH)

  2          2.05, m; 1.36, m       31.5 (CH~2~)    1.98, m; 1.40, m              32.5 (CH~2~)

  3          2.81, dd (10.0, 4.0)   60.1 (CH)       2.77, dd; (9.6, 4.4)          59.4 (CH)

  4                                 60.2 (C)                                      60.7 (C)

  5          2.00, m; 1.59, m       36.9 (CH~2~)    1.99, m; 1.54, m              36.8 (CH~2~)

  6          2.12, m; 2.08, m       22.2 (CH~2~)    2.10, m; 2.00, m              22.9 (CH~2~)

  7          5.18, t (5.6)          126.5 (CH)      5.11, t (5.2)                 126.4 (CH)

  8                                 134.2 (C)                                     134.6 (C)

  9          2.26, m; 2.09, m       36.0 (CH~2~)    2.55, m, 2.22, m              31.6 (CH~2~)

  10         2.09, m; 1.40, m       24.6 (CH~2~     2.71, ddd (10.8, 8.0, 2.8)    34.3 (CH~2~)

                                                    2.65, ddd (10.8, 8.0, 2.8)    

  11         2.65, dd (10.0, 3.2)   61.9 (CH)                                     213.6 (C)

  12                                60.8 (C)                                      78.8 (C)

  13         1.70, m; 1.20, m       33.0 (CH~2~)    1.74, ddd (12.8, 5.6. 2.0)\   36.1 (CH~2~)
                                                    1.48, m                       

  14         1.70, m; 1.58, m       27.4 (CH~2~)    1.54, m, 1.37, m              25.2 (CH~2~)

  15                                142.7 (C)                                     142.2 (C)

  16                                167.3 (C)                                     167.4 (C)

  17         6.26, s; 5.48, s       124.4 (CH~2~)   6.31, s, 5.49, s              124.4 (CH~2~)

  18         1.29, s                17.8 (CH~3~)    1.27, s                       18.2 (CH~3~)

  19         1.65, s                15.3 (CH~3~)    1.66, s                       17.1 (CH~3~)

  20         1.23, s                17.0 (CH~3~)    1.34, s                       25.7 (CH~3~)

  16-OMe     3.76, s                52.0 (CH~3~)    3.76, s                       52.0 (CH~3~)
  -----------------------------------------------------------------------------------------------

^a^ Spectra recorded at 400 MHz in CDCl~3~. ^b^ Spectra recorded at 100 MHz in CDCl~3~. ^c^ *J* values (in Hz) in parentheses. ^d^ Attached protons were deduced by DEPT experiments.
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###### 

^1^H, ^13^C NMR data, COSY, and HMBC correlations of **3**.

  Position   *δ*~H~ ^a^ (*J* in Hz) ^c^   *δ*~C~ ^b^ (mult.) ^d^   COSY       HMBC
  ---------- ---------------------------- ------------------------ ---------- ------------------
  1          2.13, m                      34.5 (CH)                H-2, 14    C-3, 16
  2          1.78, m; 1.38, m             30.7 (CH~2~)             H-1, 3     C-1, 3, 14, 15
  3          2.74, dd (7.5, 6.5)          61.9 (CH)                H-2        C-2
  4                                       58.8 (C)                            
  5          2.44, d (7.5)                41.2 (CH~2~)             H-6        C-3, 4, 6, 7, 18
  6          6.73, m                      142.2 (CH)               H-5, 7     C-4, 5, 7, 8
  7          6.12, d (16.0)               134.0 (CH)               H-6        C-8
  8                                       198.3 (C)                           
  9          1.82, m                      20.8 (CH~2~)             H-10, 17   C-15
  10         2.05, m; 1.68, m             34.1 (CH~2~)             H-9        C-9, 11, 12
  11                                      85.3 (C)                            
  12                                      84.7 (C)                            
  13         2.10, m; 1.72, m             30.4 (CH~2~)                        C-11, 12
  14         1.96, m; 1.22, m             25.8 (CH~2~)                        C-12, 15
  15                                      60.9 (C)                            
  16                                      177.6 (C)                           
  17         2.26, m; 1.66, m             28.4 (CH~2~)             H-9        C-1, 15, 16
  18         1.28, s                      17.2 (CH~3~)                        C-3, 4, 5
  19         2.26, s                      27.0 (CH~3~)                        C-7, 8
  20         1.39, s                      18.7 (CH~3~)                        C-11, 12, 13

^a^ Spectra recorded at 500 MHz in CDCl~3~. ^b^ Spectra recorded at 125 MHz in CDCl~3~. ^c^ *J* values (in Hz) in parentheses. ^d^ Attached protons were deduced by DEPT experiments.
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###### 

^1^H and ^13^C NMR data of compounds **4** and **5.**

  Position   4                      5                                      
  ---------- ---------------------- --------------- ---------------------- ---------------
  1          2.02, m                35.9 (CH)       2.92, m                34.6 (CH)
  2          1.07, m; 1.02, m       28.2 (CH~2~)    2.14, m; 1.48, m       33.3 (CH~2~)
  3          3.64, dd (11.6)        83.0 (CH)       3.07, dd (10.0, 4.0)   61.7 (CH)
  4                                 72.5 (C)                               59.6 (C)
  5          2.14, m; 1.97, m       41.3 (CH~2~)    2.12, m; 1.48, m       34.3 (CH~2~)
  6          5.66, m                124.1 (CH)      1.94, m; 1.91, m       25.5 (CH~2~)
  7          5.20, dd (15.6, 6.8)   136.9 (CH)      4.53, d (10.0)         81.2 (CH)
  8                                 83.9 (C)                               145.8 (C)
  9          1.44, m; 1.22, m       33.9 (CH~2~)    2.59, m; 2.23, m       29.7 (CH~2~)
  10         2.05, m; 1.94, m       28.7 (CH~2~)    1.89, m; 1.78, m       26.5 (CH~2~)
  11                                175.4 (C)       5.60, dd (12.8, 2.4)   72.9 (CH)
  12                                205.6 (C)                              87.1 (C)
  13         1.76, m; 1.68, m       39.4 (CH~2~)    2.03, m; 1.92, m       32.8 (CH~2~)
  14         1.62, m; 1.32, m       28.0 (CH~2~)    2.23, m; 1.38, m       30.1 (CH~2~)
  15                                139.5 (C)                              143.4 (C)
  16                                165.3 (C)                              168.1 (C)
  17         6.40, s; 5.12, s       126.0 (CH~2~)   6.30, s; 5.50, s       125.0 (CH~2~)
  18         1.00 s                 22.4 (CH~3~)    1.40 s                 24.0 (CH~3~)
  19         1.04 s                 26.3 (CH~3~)    5.09 s; 5.06 s         115.0 (CH~2~)
  20         1.64 s                 29.4 (CH~3~)    1.38 s                 15.5 (CH~3~)
  OAc                                               2.09 s                 20.9 (CH~3~)
                                                                           170.6 (C)

^a^ Spectra recorded at 400 MHz in C~6~D~6~. ^b^ Spectra recorded at 100 MHz in C~6~D~6~. ^c^ Spectra recorded at 400 MHz in CDCl~3~. ^d^ Spectra recorded at 100 MHz in CDCl~3~. ^e^ J values (in Hz) in parentheses. ^f^ Attached protons were deduced by DEPT experiments.
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###### 

The cytotoxic activity of **7**--**9** and **11** ^a^.

  Compound                        IC~50~ (μM)          
  ------------------------------- ------------- ------ ------
  **7**                           9.3           23.4   15.9
  **8**                           6.9           12.2   9.6
  **9**                           16.0          26.7   (--)
  **11**                          (--) ^e^      21.7   27.1
  Doxorubicin hydrochloride ^f^   0.3           1.0    0.9

^a^ Compounds **1**, **2**, **4**--**6**, **10**, and **12**--**14** were inactive toward the three cancer cell lines with IC~50~ \> 40 μM. ^b^ P-388: murine leukemia. ^c^ K-562: human erythromyeloblastoid leukemia. ^d^ HT-29: human colon adenocarcinoma. ^e^ (--): IC~50~ \> 40 μM. ^f^ Positive control.

[^1]: These authors contributed equally to this work.
